We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis (GLADIATOR UC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04607837
Recruitment Status : Active, not recruiting
First Posted : October 29, 2020
Last Update Posted : June 28, 2022
Information provided by (Responsible Party):
Arena Pharmaceuticals

Brief Summary:
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: Etrasimod Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 162 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
Actual Study Start Date : April 19, 2021
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Etrasimod 2 mg Drug: Etrasimod
Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
Other Name: APD334

Placebo Comparator: Placebo Drug: Placebo
Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment

Primary Outcome Measures :
  1. Proportion of Participants Achieving Clinical Remission as Assessed by Total Mayo Clinic Score [ Time Frame: Week 12 ]

Secondary Outcome Measures :
  1. Proportion of Participants With Reduction From Baseline in Both Endoscopic Score and Rectal Bleeding or in Both Endoscopic Score and Stool Frequency [ Time Frame: Week 12 ]
  2. Proportion of Participants Achieving Endoscopic Improvement [ Time Frame: Week 12 ]
  3. Proportion of Participants With Histologic Response as Assessed by Robarts Histopathology Index Score [ Time Frame: Week 12 ]
  4. Proportion of Participants With a Clinical Response as Assessed by Total Mayo Clinic Score [ Time Frame: Week 12 ]
  5. Proportion of Participants Achieving Symptomatic Remission [ Time Frame: Week 12 ]
  6. Number and Severity of Adverse Events [ Time Frame: Up to approximately 56 weeks (52-Week Treatment Period and 4-Week Follow-Up Period) ]
    Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with Ulcerative Colitis (UC) ≥ 3 months prior to screening
  • Active UC confirmed by endoscopy
  • Moderately active UC defined as a modified Mayo score of 4 to 6 and an endoscopic score ≥ 1
  • Received a surveillance colonoscopy within 12 months before baseline

Exclusion Criteria:

  • Severe extensive colitis
  • Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of a fistula consistent with Crohn's disease
  • Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
  • Hospitalization for exacerbation of UC requiring intravenous steroids within 12 weeks prior to or after screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04607837

Show Show 129 study locations
Sponsors and Collaborators
Arena Pharmaceuticals
Layout table for investigator information
Study Director: Arena CT.gov Administrator Arena Pharmaceuticals
Layout table for additonal information
Responsible Party: Arena Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04607837    
Other Study ID Numbers: APD334-210
First Posted: October 29, 2020    Key Record Dates
Last Update Posted: June 28, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Arena Pharmaceuticals:
Ulcerative colitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases